Dx Deals: Seeking Expanded MRD Testing, Natera Acquires Foresight Diagnostics in $450M Deal
Agreement is part of the Natera’s aggressive growth model as it strives to turn a profit
Already a member? Log in here
When Is Genome Sequencing Advisable?
With patient and provider demand for WGS on the rise, what should laboratorians know about ordering and interpreting this testing?
Already a member? Log in here
Expert Q&A: What’s Next in Next-Generation Sequencing?
Crystal Girod, MSc, of Beckman Coulter Life Sciences discusses recent developments in NGS and their impact on clinical diagnostics.
Already a member? Log in here
Which Test? Choosing the Best Approach to Diagnosing Rare Disease
Genomic sequencing is almost twice as likely to yield a diagnostic result, but lags behind panel testing in speed, cost, and concordance.
Already a member? Log in here
ACMG Statements Highlight Ongoing Concerns around Polygenic Risk Scores
Though there are currently no clinical guidelines for their use, PRSs are being widely used in health care.
Already a member? Log in here